Page last updated: 2024-09-04

vatalanib and Lymph Node Metastasis

vatalanib has been researched along with Lymph Node Metastasis in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bold, G; Brüggen, J; Furet, P; Haberey, M; Huth, A; Krüger, M; Manley, PW; Menrad, A; Mestan, J; Meyer, T; Ottow, E; Schnell, CR; Seidelmann, D; Siemeister, G; Thierauch, KH; Wood, J1
Alsop, DC; De Bazelaire, C; Duhamel, G; George, D; Michaelson, MD; Rofsky, NM1
Drevs, J; Hofmann, I; Hugenschmidt, H; Madjar, H; Marmé, D; Martiny-Baron, G; Müller, M; Unger, C; Wittig, C; Wood, J1

Trials

1 trial(s) available for vatalanib and Lymph Node Metastasis

ArticleYear
Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).
    Academic radiology, 2005, Volume: 12, Issue:3

    Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Contrast Media; Feasibility Studies; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow; Spin Labels

2005

Other Studies

2 other study(ies) available for vatalanib and Lymph Node Metastasis

ArticleYear
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.
    Journal of medicinal chemistry, 2002, Dec-19, Volume: 45, Issue:26

    Topics: Administration, Oral; Amides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; Enzyme Inhibitors; Female; Humans; Isoquinolines; Lymphatic Metastasis; Melanoma; Mice; ortho-Aminobenzoates; Phosphorylation; Receptors, Vascular Endothelial Growth Factor

2002
Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Cancer research, 2000, Sep-01, Volume: 60, Issue:17

    Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Carcinoma, Renal Cell; Cell Division; Cyclohexanes; Disease Models, Animal; Enzyme Inhibitors; Female; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Renal Circulation; Sesquiterpenes

2000